* Compass Therapeutics (NASDAQ:CMPX [https://seekingalpha.com/symbol/CMPX]) priced [https://seekingalpha.com/pr/20198896-compass-therapeutics-announces-pricing-of-upsized-120-million-public-offering] an underwritten public offering of 33.29M shares at $3.00 per share and pre-funded warrants to purchase up to 6.67M shares.
* The gross proceeds are expected to be ~$120M.
* The offering is expected to close on or about August 14, 2025.
* Underwriters have a 30-day option to purchase up to 6M additional shares.
* Net proceeds will be used to conduct initial preparations for commercial readiness, to fund research and clinical development of its product candidates, and for general corporate purposes.
* The stock price traded 5% lower on Tuesday during after-market hours of trading.
MORE ON COMPASS THERAPEUTICS
* Compass Therapeutics announces proposed public offering [https://seekingalpha.com/news/4484211-compass-therapeutics-announces-proposed-public-offering]
* Compass Therapeutics rises after pipeline updates [https://seekingalpha.com/news/4483347-compass-therapeutics-stock-rises-pipeline-updates]
* Seeking Alpha’s Quant Rating on Compass Therapeutics [https://seekingalpha.com/symbol/CMPX/ratings/quant-ratings]
* Historical earnings data for Compass Therapeutics [https://seekingalpha.com/symbol/CMPX/earnings]
* Financial information for Compass Therapeutics [https://seekingalpha.com/symbol/CMPX/income-statement]
Compass Therapeutics dips 5%, prices $120M stock
Published 2 months ago
Aug 13, 2025 at 5:48 AM
Positive
Auto